VX-407

Phase 2Small molecule

VX-407 is one of 61 small molecule programs targeting Autosomal Dominant Polycystic Kidney Disease. It is currently in Phase 2.

Indications

Total Trials

Active Trials

Competitors

Pipeline

Status by Indication[3][1]

Indication

Autosomal Dominant Polycystic Kidney DiseaseActive, not recruiting

Phase 1Active, not recruiting

OralActive, not recruiting

Autosomal Dominant Polycystic Kidney DiseasePhase 2

Active, not recruiting

Phase 1Phase 1

Active, not recruiting

OralPhase 1

Active, not recruiting

Competition

Competitive Landscape

52 competitors in Phase 1

#DrugCompanyPhaseTrials

Venclexta

AbbVie

Phase 2

2 2

Cytoxan

BBaxter Healthcare Corporation

Phase 2

4 3

Erbitux

IImclone

Phase 2

3 4

Rayos

RRoxane Laboratories

Phase 2

1 5

Navitoclax

AbbVie

Phase 2

1 6

Fludara

Sanofi

Phase 1

3 7

Yervoy

Bristol-Myers Squibb

Phase 1

1 8

VX-407

Vertex Pharmaceuticals

Phase 2

2 9

Benznidazole

CCorestemchemon, Inc.

Phase 1

1 10

Radiprodil

GGRIN Therapeutics, Inc.

Phase 1

Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.

Timeline

Expected Milestones

Q1 2027

Phase 1Recruiting

Autosomal Dominant Polycystic Kidney Disease

NCT07792408

Q4 2027

Phase 2Active, not recruiting

Autosomal Dominant Polycystic Kidney Disease

NCT07161037

Clinical

Trials by Indication[1]

Phase 12 trials

A Phase 1 Study to Evaluate Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Completed· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT06345755·159 enrolled

A Phase 1 Study Evaluating Safety, Tolerability, and Pharmacokinetics of VX-407 in Healthy Participants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07022119·32 enrolled

Autosomal Dominant Polycystic Kidney Disease2 trials

A Phase 1, Open-label Drug Interaction Study to Evaluate the Effect of VX-407 on the Pharmacokinetics of Combined Oral Contraceptives

Recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07792408·148 enrolled

A Phase 2a, Open-label, Single-arm Study to Evaluate the Efficacy, Safety, and Pharmacokinetics of VX-407 in Subjects With Autosomal Dominant Polycystic Kidney Disease Who Have a Subset of PKD1 Gene Variants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 2·NCT07161037·26 enrolled

Oral1 trial

Effects of VX-407 on the Pharmacokinetics of Oral Contraceptives in Healthy Participants

Active, not recruiting· Vertex Pharmaceuticals logo

Vertex Pharmaceuticals·Phase 1·NCT07074327·74 enrolled

Sources

References

[1]
ClinicalTrials.gov — 5 trial records for VX-407. U.S. National Library of Medicine, National Institutes of Health.
[2]
ChEMBL — VX-407 compound record. European Bioinformatics Institute (EMBL-EBI).
[3]
Open Targets Platform — Drug–disease associations for VX-407. EMBL-EBI & Wellcome Sanger Institute.
[4]
SEC EDGAR — Vertex Pharmaceuticals company filings. U.S. Securities and Exchange Commission.

Details

Drug Info

Quick Facts

Modality: Small molecule[2]
Highest Phase: Phase 2[1]
Company: Vertex Pharmaceuticals

VX-407

Status by Indication[3][1]

Competitive Landscape

Expected Milestones

Q1 2027

Q4 2027

Trials by Indication[1]

Phase 12 trials

Autosomal Dominant Polycystic Kidney Disease2 trials

Oral1 trial

References

Drug Info

Quick Facts

Related News